home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Molecular Tug Of War Predicts Tamoxifen Response

  November, 26 2008 18:08
your information resource in human molecular genetics

A mechanism behind resistance to the anti-cancer drug tamoxifen in breast cancer is reported online in Nature. The research could be used to predict the outcome of tamoxifen therapy.

Tamoxifen stops tumour growth by binding to the oestrogen receptor and blocking expression of ERBB2/HER-2 - a receptor that causes cells to divide. Jason Carroll and colleagues identify PAX2 as the regulatory molecule that transmits this blocking signal by switching off the ERBB2 gene. When they looked for PAX2 in tumour samples from patients receiving tamoxifen treatment, they found that high levels of PAX2 are associated with improved survival.

In contrast, drug-resistant tumours have higher levels of another molecule - AIB-1 - which competes with PAX2 in a molecular tug of war to initiate ERBB2/HER-2 expression. Overall, the team find that the ratio of PAX2 to AIB-1 predicts the efficacy of tamoxifen therapy in breast cancer.


Jason Carroll (Cancer Research UK Cambridge Research Institute, UK)
E-mail: Jason.Carroll@cancer.org.uk

Abstract available online.

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2018 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.